ENSG00000147889 |
|
Borderline Ovarian Mucinous Tumor |
missense_variant |
34.85% (23/66) |
1 entry |
ENSG00000147889 |
|
Borderline Ovarian Mucinous Tumor |
transcript_ablation |
34.85% (23/66) |
1 entry |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
10.5% (146/1391) |
15 entries |
ENSG00000147889 |
|
skin melanoma |
missense_variant |
18.53% (470/2537) |
34 entries |
ENSG00000147889 |
|
Vulvar Squamous Cell Carcinoma |
missense_variant |
18.8% (25/133) |
5 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
stop_lost |
14.25% (221/1551) |
2 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
15.72% (420/2671) |
31 entries |
ENSG00000147889 |
|
T-cell acute lymphoblastic leukemia |
transcript_ablation |
30.46% (396/1300) |
14 entries |
ENSG00000147889 |
|
bladder transitional cell carcinoma |
transcript_ablation |
13.84% (224/1618) |
6 entries |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
missense_variant |
10.5% (146/1391) |
9 entries |
ENSG00000147889 |
|
laryngeal squamous cell carcinoma |
missense_variant |
17.76% (81/456) |
11 entries |
ENSG00000147889 |
|
nodular melanoma |
sequence_alteration |
26.57% (38/143) |
4 entries |
ENSG00000147889 |
|
Pleural Mesothelioma |
transcript_ablation |
37.86% (145/383) |
5 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
transcript_ablation |
15.72% (420/2671) |
4 entries |
ENSG00000147889 |
|
anaplastic astrocytoma |
sequence_alteration |
13.45% (64/476) |
9 entries |
ENSG00000147889 |
|
brain glioblastoma |
missense_variant |
17.55% (486/2769) |
9 entries |
ENSG00000147889 |
|
B-cell acute lymphoblastic leukemia |
sequence_alteration |
16.29% (165/1013) |
14 entries |
ENSG00000147889 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
14.61% (45/308) |
4 entries |
ENSG00000147889 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
30.46% (396/1300) |
5 entries |
ENSG00000147889 |
|
bladder transitional cell carcinoma |
frameshift_variant |
13.84% (224/1618) |
3 entries |
ENSG00000147889 |
|
Pleural Mesothelioma |
sequence_alteration |
37.86% (145/383) |
5 entries |
ENSG00000147889 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
16.29% (165/1013) |
4 entries |
ENSG00000147889 |
|
Central Nervous System Lymphoma |
sequence_alteration |
41.67% (30/72) |
1 entry |
ENSG00000147889 |
|
ovarian mucinous adenocarcinoma |
stop_gained |
19.05% (24/126) |
4 entries |
ENSG00000147889 |
|
laryngeal squamous cell carcinoma |
sequence_alteration |
17.76% (81/456) |
10 entries |
ENSG00000147889 |
|
brain glioblastoma |
sequence_alteration |
17.55% (486/2769) |
21 entries |
ENSG00000147889 |
|
Vulvar Squamous Cell Carcinoma |
stop_gained |
18.8% (25/133) |
4 entries |
ENSG00000147889 |
|
non-small cell lung carcinoma |
stop_gained |
10.59% (145/1369) |
7 entries |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
stop_gained |
10.5% (146/1391) |
9 entries |
ENSG00000147889 |
|
Gallbladder Adenocarcinoma |
stop_lost |
14.61% (45/308) |
1 entry |
ENSG00000147889 |
|
Central Nervous System Lymphoma |
transcript_ablation |
41.67% (30/72) |
2 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
15.72% (420/2671) |
15 entries |
ENSG00000147889 |
|
Pleural Sarcomatoid Mesothelioma |
transcript_ablation |
62.16% (23/37) |
2 entries |
ENSG00000147889 |
|
Borderline Ovarian Mucinous Tumor |
sequence_alteration |
34.85% (23/66) |
3 entries |
ENSG00000147889 |
|
oral squamous cell carcinoma |
missense_variant |
17.62% (173/982) |
23 entries |
ENSG00000147889 |
|
bladder transitional cell carcinoma |
sequence_alteration |
13.84% (224/1618) |
14 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
stop_gained |
14.25% (221/1551) |
15 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
stop_gained |
15.72% (420/2671) |
14 entries |
ENSG00000147889 |
|
ovarian mucinous adenocarcinoma |
missense_variant |
19.05% (24/126) |
6 entries |
ENSG00000147889 |
|
Gallbladder Adenocarcinoma |
missense_variant |
14.61% (45/308) |
5 entries |
ENSG00000147889 |
|
anaplastic astrocytoma |
missense_variant |
13.45% (64/476) |
4 entries |
ENSG00000147889 |
|
anaplastic oligodendroglioma |
sequence_alteration |
20.67% (99/479) |
3 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
missense_variant |
14.25% (221/1551) |
16 entries |
ENSG00000147889 |
|
laryngeal squamous cell carcinoma |
stop_gained |
17.76% (81/456) |
7 entries |
ENSG00000147889 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
30.46% (396/1300) |
8 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
15.72% (420/2671) |
23 entries |
ENSG00000147889 |
|
hemangioblastoma |
sequence_alteration |
61.11% (22/36) |
1 entry |
ENSG00000147889 |
|
skin melanoma |
frameshift_variant |
18.53% (470/2537) |
12 entries |
ENSG00000147889 |
|
Gallbladder Adenocarcinoma |
transcript_ablation |
14.61% (45/308) |
1 entry |
ENSG00000147889 |
|
oral squamous cell carcinoma |
stop_gained |
17.62% (173/982) |
18 entries |
ENSG00000147889 |
|
Borderline Ovarian Mucinous Tumor |
stop_gained |
34.85% (23/66) |
2 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
14.25% (221/1551) |
22 entries |
ENSG00000147889 |
|
laryngeal squamous cell carcinoma |
transcript_ablation |
17.76% (81/456) |
1 entry |
ENSG00000147889 |
|
Gallbladder Adenocarcinoma |
stop_gained |
14.61% (45/308) |
2 entries |
ENSG00000147889 |
|
nodular melanoma |
stop_gained |
26.57% (38/143) |
3 entries |
ENSG00000147889 |
|
anaplastic oligodendroglioma |
missense_variant |
20.67% (99/479) |
2 entries |
ENSG00000147889 |
|
bladder transitional cell carcinoma |
stop_gained |
13.84% (224/1618) |
5 entries |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
transcript_ablation |
10.5% (146/1391) |
3 entries |
ENSG00000147889 |
|
non-small cell lung carcinoma |
frameshift_variant |
10.59% (145/1369) |
6 entries |
ENSG00000147889 |
|
ovarian mucinous adenocarcinoma |
amino_acid_insertion |
19.05% (24/126) |
2 entries |
ENSG00000147889 |
|
nodular melanoma |
transcript_ablation |
26.57% (38/143) |
6 entries |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
frameshift_variant |
10.5% (146/1391) |
6 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
conservative_inframe_deletion |
14.25% (221/1551) |
4 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
amino_acid_insertion |
15.72% (420/2671) |
5 entries |
ENSG00000147889 |
|
non-small cell lung carcinoma |
transcript_ablation |
10.59% (145/1369) |
6 entries |
ENSG00000147889 |
|
non-small cell lung carcinoma |
missense_variant |
10.59% (145/1369) |
13 entries |
ENSG00000147889 |
|
anaplastic astrocytoma |
transcript_ablation |
13.45% (64/476) |
12 entries |
ENSG00000147889 |
|
skin melanoma |
transcript_ablation |
18.53% (470/2537) |
13 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
14.25% (221/1551) |
17 entries |
ENSG00000147889 |
|
brain glioblastoma |
frameshift_variant |
17.55% (486/2769) |
5 entries |
ENSG00000147889 |
|
oral squamous cell carcinoma |
frameshift_variant |
17.62% (173/982) |
8 entries |
ENSG00000147889 |
|
bladder transitional cell carcinoma |
missense_variant |
13.84% (224/1618) |
10 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
conservative_inframe_deletion |
15.72% (420/2671) |
5 entries |
ENSG00000147889 |
|
B-cell acute lymphoblastic leukemia |
transcript_ablation |
16.29% (165/1013) |
8 entries |
ENSG00000147889 |
|
brain glioblastoma |
transcript_ablation |
17.55% (486/2769) |
22 entries |
ENSG00000147889 |
|
ovarian mucinous adenocarcinoma |
sequence_alteration |
19.05% (24/126) |
4 entries |
ENSG00000147889 |
|
oral squamous cell carcinoma |
transcript_ablation |
17.62% (173/982) |
4 entries |
ENSG00000147889 |
|
non-small cell lung carcinoma |
sequence_alteration |
10.59% (145/1369) |
14 entries |
ENSG00000147889 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
30.46% (396/1300) |
19 entries |
ENSG00000147889 |
|
laryngeal squamous cell carcinoma |
conservative_inframe_deletion |
17.76% (81/456) |
2 entries |
ENSG00000147889 |
|
skin melanoma |
stop_gained |
18.53% (470/2537) |
26 entries |
ENSG00000147889 |
|
nodular melanoma |
missense_variant |
26.57% (38/143) |
6 entries |
ENSG00000147889 |
|
brain glioblastoma |
stop_gained |
17.55% (486/2769) |
5 entries |
ENSG00000147889 |
|
B-cell acute lymphoblastic leukemia |
stop_gained |
16.29% (165/1013) |
1 entry |
ENSG00000147889 |
|
ovarian mucinous adenocarcinoma |
frameshift_variant |
19.05% (24/126) |
3 entries |
ENSG00000147889 |
|
oral squamous cell carcinoma |
sequence_alteration |
17.62% (173/982) |
19 entries |
ENSG00000147889 |
|
skin melanoma |
conservative_inframe_deletion |
18.53% (470/2537) |
3 entries |
ENSG00000147889 |
|
oral squamous cell carcinoma |
conservative_inframe_deletion |
17.62% (173/982) |
2 entries |
ENSG00000147889 |
|
skin melanoma |
sequence_alteration |
18.53% (470/2537) |
27 entries |
ENSG00000147889 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
30.46% (396/1300) |
6 entries |
ENSG00000147889 |
|
laryngeal squamous cell carcinoma |
frameshift_variant |
17.76% (81/456) |
7 entries |
ENSG00000147889 |
|
Bladder Squamous Cell Carcinoma |
sequence_alteration |
56.45% (35/62) |
1 entry |
ENSG00000147889 |
|
anaplastic oligodendroglioma |
transcript_ablation |
20.67% (99/479) |
5 entries |
ENSG00000147889 |
|
esophageal squamous cell carcinoma |
transcript_ablation |
14.25% (221/1551) |
3 entries |
ENSG00000147889 |
|
Barrett's esophagus |
frameshift_variant |
10.95% (38/347) |
1 entry |
ENSG00000147889 |
|
papillary thyroid carcinoma |
frameshift_variant |
3.307% (21/635) |
2 entries |
ENSG00000147889 |
|
colon adenocarcinoma |
stop_gained |
2.561% (37/1445) |
3 entries |
ENSG00000147889 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
5.567% (28/503) |
6 entries |
ENSG00000147889 |
|
pancreatic carcinoma |
sequence_alteration |
16.52% (19/115) |
1 entry |
ENSG00000147889 |
|
colon adenocarcinoma |
frameshift_variant |
2.561% (37/1445) |
2 entries |
ENSG00000147889 |
|
angioimmunoblastic T-cell lymphoma |
missense_variant |
3.053% (4/131) |
1 entry |
ENSG00000147889 |
|
lung adenocarcinoma |
stop_gained |
6.213% (231/3718) |
7 entries |
ENSG00000147889 |
|
Barrett's esophagus |
stop_gained |
10.95% (38/347) |
2 entries |
ENSG00000147889 |
|
bladder carcinoma |
sequence_alteration |
6.078% (62/1020) |
4 entries |
ENSG00000147889 |
|
metaplastic breast carcinoma |
transcript_ablation |
9.412% (8/85) |
2 entries |
ENSG00000147889 |
|
lung carcinoma |
missense_variant |
6.79% (11/162) |
1 entry |
ENSG00000147889 |
|
anaplastic astrocytoma |
frameshift_variant |
13.45% (64/476) |
1 entry |
ENSG00000147889 |
|
ovarian teratoma |
missense_variant |
16.92% (11/65) |
1 entry |
ENSG00000147889 |
|
acute lymphoblastic leukemia |
sequence_alteration |
9.167% (55/600) |
7 entries |
ENSG00000147889 |
|
glioma |
missense_variant |
7.333% (80/1091) |
2 entries |
ENSG00000147889 |
|
esophageal carcinoma |
missense_variant |
3.589% (15/418) |
1 entry |
ENSG00000147889 |
|
sebaceous adenocarcinoma |
stop_gained |
80.0% (4/5) |
1 entry |
ENSG00000147889 |
|
glioma |
sequence_alteration |
7.333% (80/1091) |
5 entries |
ENSG00000147889 |
|
colorectal adenocarcinoma |
frameshift_variant |
2.022% (33/1632) |
4 entries |
ENSG00000147889 |
|
rectal adenocarcinoma |
sequence_alteration |
0.8596% (6/698) |
2 entries |
ENSG00000147889 |
|
lobular breast carcinoma |
sequence_alteration |
1.484% (5/337) |
2 entries |
ENSG00000147889 |
|
adenosquamous lung carcinoma |
sequence_alteration |
6.25% (2/32) |
2 entries |
ENSG00000147889 |
|
clear cell renal carcinoma |
conservative_inframe_deletion |
1.951% (38/1948) |
1 entry |
ENSG00000147889 |
|
neoplasm of mature B-cells |
sequence_alteration |
3.235% (11/340) |
2 entries |
ENSG00000147889 |
|
squamous cell carcinoma |
missense_variant |
33.33% (9/27) |
1 entry |
ENSG00000147889 |
|
Undifferentiated Ovarian Carcinoma |
sequence_alteration |
11.76% (2/17) |
1 entry |
ENSG00000147889 |
|
acute leukemia of ambiguous lineage |
sequence_alteration |
1.37% (2/146) |
1 entry |
ENSG00000147889 |
|
Thymic Carcinoma |
missense_variant |
15.0% (9/60) |
2 entries |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
stop_lost |
10.5% (146/1391) |
1 entry |
ENSG00000147889 |
|
Bladder Squamous Cell Carcinoma |
stop_gained |
56.45% (35/62) |
1 entry |
ENSG00000147889 |
|
Ovarian Endometrioid Adenocarcinoma |
sequence_alteration |
6.977% (6/86) |
2 entries |
ENSG00000147889 |
|
chronic myelogenous leukemia |
missense_variant |
11.41% (21/184) |
1 entry |
ENSG00000147889 |
|
adrenal gland pheochromocytoma |
missense_variant |
2.19% (6/274) |
2 entries |
ENSG00000147889 |
|
Pleural Epithelioid Mesothelioma |
transcript_ablation |
12.58% (41/326) |
3 entries |
ENSG00000147889 |
|
urothelial carcinoma |
stop_gained |
6.522% (6/92) |
1 entry |
ENSG00000147889 |
|
head and neck squamous cell carcinoma |
conservative_inframe_deletion |
10.5% (146/1391) |
1 entry |
ENSG00000147889 |
|
large cell lung carcinoma |
missense_variant |
10.81% (12/111) |
2 entries |
ENSG00000147889 |
|
acute myeloid leukemia |
sequence_alteration |
0.8177% (27/3302) |
10 entries |
ENSG00000147889 |
|
Malignant Mesothelioma |
transcript_ablation |
33.33% (2/6) |
1 entry |
ENSG00000147889 |
|
melanocytic neoplasm |
sequence_alteration |
18.52% (10/54) |
1 entry |
ENSG00000147889 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
9.813% (42/428) |
3 entries |
ENSG00000147889 |
|
bronchoalveolar adenocarcinoma |
transcript_ablation |
16.67% (12/72) |
3 entries |
ENSG00000147889 |
|
pharyngeal squamous cell carcinoma |
stop_gained |
8.284% (28/338) |
3 entries |
ENSG00000147889 |
|
Mixed Cell Uveal Melanoma |
sequence_alteration |
5.263% (4/76) |
1 entry |
ENSG00000147889 |
|
neoplasm of mature B-cells |
stop_gained |
3.235% (11/340) |
1 entry |
ENSG00000147889 |
|
bladder carcinoma |
missense_variant |
6.078% (62/1020) |
4 entries |
ENSG00000147889 |
|
Salivary Gland Carcinoma ex Pleomorphic Adenoma |
transcript_ablation |
4.0% (2/50) |
1 entry |
ENSG00000147889 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
5.567% (28/503) |
6 entries |
ENSG00000147889 |
|
Burkitts lymphoma |
sequence_alteration |
4.938% (12/243) |
3 entries |
ENSG00000147889 |
|
small cell lung carcinoma |
missense_variant |
2.45% (16/653) |
4 entries |
ENSG00000147889 |
|
breast carcinoma |
frameshift_variant |
1.577% (33/2093) |
4 entries |
ENSG00000147889 |
|
prostate adenocarcinoma |
missense_variant |
1.213% (30/2473) |
7 entries |
ENSG00000147889 |
|
female breast carcinoma |
sequence_alteration |
2.817% (18/639) |
2 entries |
ENSG00000147889 |
|
dysplasia |
sequence_alteration |
18.18% (4/22) |
1 entry |
ENSG00000147889 |
|
salivary gland squamous cell carcinoma |
missense_variant |
100.0% (2/2) |
1 entry |
ENSG00000147889 |
|
Anal Squamous Cell Carcinoma |
sequence_alteration |
2.41% (2/83) |
1 entry |
ENSG00000147889 |
|
osteosarcoma |
frameshift_variant |
7.125% (28/393) |
2 entries |
ENSG00000147889 |
|
dysplasia |
missense_variant |
18.18% (4/22) |
1 entry |
ENSG00000147889 |
|
Gastrointestinal stromal tumor |
transcript_ablation |
6.173% (15/243) |
4 entries |
ENSG00000147889 |
|
lung adenocarcinoma |
missense_variant |
6.213% (231/3718) |
15 entries |
ENSG00000147889 |
|
ovarian teratoma |
transcript_ablation |
16.92% (11/65) |
1 entry |
ENSG00000147889 |
|
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type |
transcript_ablation |
100.0% (2/2) |
1 entry |
ENSG00000147889 |
|
Gastric Neuroendocrine Tumor G1 |
sequence_alteration |
13.33% (2/15) |
2 entries |
ENSG00000147889 |
|
carcinoma of liver and intrahepatic biliary tract |
sequence_alteration |
4.613% (34/737) |
2 entries |
ENSG00000147889 |
|
small cell lung carcinoma |
frameshift_variant |
2.45% (16/653) |
3 entries |
ENSG00000147889 |
|
Pleural Epithelioid Mesothelioma |
sequence_alteration |
12.58% (41/326) |
3 entries |
ENSG00000147889 |
|
bladder carcinoma |
transcript_ablation |
6.078% (62/1020) |
1 entry |
ENSG00000147889 |
|
osteosarcoma |
sequence_alteration |
7.125% (28/393) |
1 entry |
ENSG00000147889 |
|
clear cell renal carcinoma |
transcript_ablation |
1.951% (38/1948) |
2 entries |
ENSG00000147889 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
9.813% (42/428) |
2 entries |
ENSG00000147889 |
|
lung adenocarcinoma |
sequence_alteration |
6.213% (231/3718) |
14 entries |
ENSG00000147889 |
|
Pancreatic Gastrinoma |
sequence_alteration |
11.54% (3/26) |
2 entries |
ENSG00000147889 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.43% (19/1329) |
5 entries |
ENSG00000147889 |
|
Bladder Squamous Cell Carcinoma |
missense_variant |
56.45% (35/62) |
1 entry |
ENSG00000147889 |
|
papillary thyroid carcinoma |
transcript_ablation |
3.307% (21/635) |
2 entries |
ENSG00000147889 |
|
acute lymphoblastic leukemia |
transcript_ablation |
9.167% (55/600) |
4 entries |
ENSG00000147889 |
|
acute myeloid leukemia |
transcript_ablation |
0.8177% (27/3302) |
3 entries |
ENSG00000147889 |
|
gastric adenocarcinoma |
stop_gained |
2.334% (33/1414) |
3 entries |
ENSG00000147889 |
|
gastric intestinal type adenocarcinoma |
sequence_alteration |
3.526% (11/312) |
3 entries |
ENSG00000147889 |
|
esophageal adenocarcinoma |
stop_gained |
9.314% (72/773) |
3 entries |
ENSG00000147889 |
|
esophageal adenocarcinoma |
missense_variant |
9.314% (72/773) |
2 entries |
ENSG00000147889 |
|
ovarian clear cell adenocarcinoma |
transcript_ablation |
7.692% (11/143) |
2 entries |
ENSG00000147889 |
|
anaplastic oligoastrocytoma |
transcript_ablation |
11.42% (25/219) |
1 entry |
ENSG00000147889 |
|
esophageal adenocarcinoma |
conservative_inframe_deletion |
9.314% (72/773) |
3 entries |
ENSG00000147889 |
|
lung adenocarcinoma |
conservative_inframe_deletion |
6.213% (231/3718) |
1 entry |
ENSG00000147889 |
|
Mantle cell lymphoma |
sequence_alteration |
5.833% (14/240) |
2 entries |
ENSG00000147889 |
|
plexiform neurofibroma |
transcript_ablation |
18.18% (6/33) |
1 entry |
ENSG00000147889 |
|
cervical squamous cell carcinoma |
sequence_alteration |
5.274% (26/493) |
3 entries |
ENSG00000147889 |
|
Pleural Biphasic Mesothelioma |
transcript_ablation |
14.63% (18/123) |
3 entries |
ENSG00000147889 |
|
breast phyllodes tumor |
missense_variant |
7.071% (7/99) |
2 entries |
ENSG00000147889 |
|
astrocytoma |
transcript_ablation |
4.762% (2/42) |
2 entries |
ENSG00000147889 |
|
pancreatic ductal adenocarcinoma |
stop_lost |
15.72% (420/2671) |
1 entry |
ENSG00000147889 |
|
esophageal adenocarcinoma |
frameshift_variant |
9.314% (72/773) |
4 entries |
ENSG00000147889 |
|
Burkitts lymphoma |
transcript_ablation |
4.938% (12/243) |
3 entries |
ENSG00000147889 |
|
Thymic Carcinoma |
transcript_ablation |
15.0% (9/60) |
1 entry |
ENSG00000147889 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
4.425% (5/113) |
1 entry |
ENSG00000147889 |
|
laryngeal carcinoma |
frameshift_variant |
12.28% (48/391) |
1 entry |
ENSG00000147889 |
|
clear cell sarcoma |
missense_variant |
10.0% (3/30) |
1 entry |
ENSG00000147889 |
|
prostate adenocarcinoma |
sequence_alteration |
1.213% (30/2473) |
5 entries |
ENSG00000147889 |
|
Merkel cell skin cancer |
sequence_alteration |
4.065% (5/123) |
2 entries |
ENSG00000147889 |
|
undifferentiated pleomorphic sarcoma |
stop_gained |
4.425% (5/113) |
1 entry |
ENSG00000147889 |
|
Mixed Lobular and Ductal Breast Carcinoma |
stop_gained |
9.231% (6/65) |
1 entry |
ENSG00000147889 |
|
gastric adenocarcinoma |
sequence_alteration |
2.334% (33/1414) |
3 entries |
ENSG00000147889 |
|
Vulvar Squamous Cell Carcinoma |
frameshift_variant |
18.8% (25/133) |
1 entry |
ENSG00000147889 |
|
head and neck carcinoma |
sequence_alteration |
83.33% (5/6) |
1 entry |
ENSG00000147889 |
|
anaplastic astrocytoma |
stop_gained |
13.45% (64/476) |
1 entry |
ENSG00000147889 |
|
lung carcinoma |
sequence_alteration |
6.79% (11/162) |
2 entries |
ENSG00000147889 |
|
bladder carcinoma |
frameshift_variant |
6.078% (62/1020) |
2 entries |
ENSG00000147889 |
|
soft tissue sarcoma |
sequence_alteration |
1.458% (5/343) |
3 entries |
ENSG00000147889 |
|
unspecified peripheral T-cell lymphoma |
sequence_alteration |
4.237% (5/118) |
2 entries |
ENSG00000147889 |
|
bile duct adenocarcinoma |
stop_gained |
3.761% (29/771) |
2 entries |
ENSG00000147889 |
|
Benign Ovarian Mucinous Tumor |
stop_gained |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
gastric adenocarcinoma |
transcript_ablation |
2.334% (33/1414) |
1 entry |
ENSG00000147889 |
|
bile duct adenocarcinoma |
transcript_ablation |
3.761% (29/771) |
2 entries |
ENSG00000147889 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
5.97% (12/201) |
4 entries |
ENSG00000147889 |
|
acute myeloid leukemia |
stop_gained |
0.8177% (27/3302) |
4 entries |
ENSG00000147889 |
|
female breast carcinoma |
transcript_ablation |
2.817% (18/639) |
2 entries |
ENSG00000147889 |
|
ovarian carcinoma |
transcript_ablation |
4.498% (13/289) |
1 entry |
ENSG00000147889 |
|
Ovarian Endometrioid Adenocarcinoma |
missense_variant |
6.977% (6/86) |
3 entries |
ENSG00000147889 |
|
hepatocellular carcinoma |
missense_variant |
5.767% (97/1682) |
8 entries |
ENSG00000147889 |
|
bile duct carcinoma |
sequence_alteration |
7.074% (22/311) |
2 entries |
ENSG00000147889 |
|
salivary gland adenoid cystic carcinoma |
sequence_alteration |
4.412% (3/68) |
2 entries |
ENSG00000147889 |
|
bile duct adenocarcinoma |
missense_variant |
3.761% (29/771) |
5 entries |
ENSG00000147889 |
|
female breast carcinoma |
stop_gained |
2.817% (18/639) |
2 entries |
ENSG00000147889 |
|
lymphoid neoplasm |
transcript_ablation |
6.376% (19/298) |
4 entries |
ENSG00000147889 |
|
skin carcinoma |
missense_variant |
8.197% (10/122) |
2 entries |
ENSG00000147889 |
|
Invasive Breast Carcinoma |
frameshift_variant |
5.797% (4/69) |
1 entry |
ENSG00000147889 |
|
soft tissue sarcoma |
transcript_ablation |
1.458% (5/343) |
1 entry |
ENSG00000147889 |
|
pharyngeal squamous cell carcinoma |
transcript_ablation |
8.284% (28/338) |
2 entries |
ENSG00000147889 |
|
diffuse large B-cell lymphoma |
stop_gained |
8.402% (81/964) |
3 entries |
ENSG00000147889 |
|
diffuse large B-cell lymphoma |
sequence_alteration |
8.402% (81/964) |
8 entries |
ENSG00000147889 |
|
squamous cell lung carcinoma |
stop_gained |
10.29% (143/1390) |
7 entries |
ENSG00000147889 |
|
clear cell renal carcinoma |
sequence_alteration |
1.951% (38/1948) |
5 entries |
ENSG00000147889 |
|
Anaplastic (Malignant) Meningioma |
missense_variant |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
myelodysplastic syndrome |
missense_variant |
0.5171% (5/967) |
1 entry |
ENSG00000147889 |
|
Anal Squamous Cell Carcinoma |
stop_gained |
2.41% (2/83) |
1 entry |
ENSG00000147889 |
|
esophageal adenocarcinoma |
transcript_ablation |
9.314% (72/773) |
4 entries |
ENSG00000147889 |
|
laryngeal carcinoma |
stop_gained |
12.28% (48/391) |
1 entry |
ENSG00000147889 |
|
malignant epithelioid mesothelioma |
transcript_ablation |
15.79% (3/19) |
2 entries |
ENSG00000147889 |
|
melanocytic neoplasm |
transcript_ablation |
18.52% (10/54) |
2 entries |
ENSG00000147889 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
1.554% (19/1223) |
4 entries |
ENSG00000147889 |
|
Chordoma |
transcript_ablation |
12.26% (13/106) |
2 entries |
ENSG00000147889 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
8.284% (28/338) |
4 entries |
ENSG00000147889 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
transcript_ablation |
5.567% (28/503) |
2 entries |
ENSG00000147889 |
|
leiomyosarcoma |
sequence_alteration |
2.525% (5/198) |
3 entries |
ENSG00000147889 |
|
cecum adenocarcinoma |
frameshift_variant |
1.444% (4/277) |
1 entry |
ENSG00000147889 |
|
ovarian serous adenocarcinoma |
transcript_ablation |
1.554% (19/1223) |
2 entries |
ENSG00000147889 |
|
bile duct carcinoma |
stop_gained |
7.074% (22/311) |
1 entry |
ENSG00000147889 |
|
rectal adenocarcinoma |
missense_variant |
0.8596% (6/698) |
3 entries |
ENSG00000147889 |
|
acute myeloid leukemia |
missense_variant |
0.8177% (27/3302) |
4 entries |
ENSG00000147889 |
|
prostate adenocarcinoma |
transcript_ablation |
1.213% (30/2473) |
1 entry |
ENSG00000147889 |
|
Pleural Biphasic Mesothelioma |
sequence_alteration |
14.63% (18/123) |
2 entries |
ENSG00000147889 |
|
Ampulla of Vater Carcinoma |
sequence_alteration |
2.03% (4/197) |
1 entry |
ENSG00000147889 |
|
epidermal appendage tumor |
missense_variant |
42.86% (3/7) |
1 entry |
ENSG00000147889 |
|
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
sequence_alteration |
9.091% (5/55) |
2 entries |
ENSG00000147889 |
|
esophageal adenocarcinoma |
sequence_alteration |
9.314% (72/773) |
5 entries |
ENSG00000147889 |
|
small cell lung carcinoma |
sequence_alteration |
2.45% (16/653) |
7 entries |
ENSG00000147889 |
|
breast ductal adenocarcinoma |
sequence_alteration |
1.388% (29/2090) |
2 entries |
ENSG00000147889 |
|
dedifferentiated chondrosarcoma |
missense_variant |
8.571% (3/35) |
1 entry |
ENSG00000147889 |
|
adrenal gland pheochromocytoma |
sequence_alteration |
2.19% (6/274) |
1 entry |
ENSG00000147889 |
|
bile duct carcinoma |
transcript_ablation |
7.074% (22/311) |
1 entry |
ENSG00000147889 |
|
squamous cell lung carcinoma |
stop_lost |
10.29% (143/1390) |
1 entry |
ENSG00000147889 |
|
gliosarcoma |
transcript_ablation |
20.0% (3/15) |
2 entries |
ENSG00000147889 |
|
skin carcinoma |
stop_gained |
8.197% (10/122) |
2 entries |
ENSG00000147889 |
|
B-cell acute lymphoblastic leukemia |
frameshift_variant |
16.29% (165/1013) |
1 entry |
ENSG00000147889 |
|
squamous cell carcinoma |
sequence_alteration |
33.33% (9/27) |
1 entry |
ENSG00000147889 |
|
colon adenocarcinoma |
missense_variant |
2.561% (37/1445) |
8 entries |
ENSG00000147889 |
|
non-small cell lung carcinoma |
conservative_inframe_deletion |
10.59% (145/1369) |
1 entry |
ENSG00000147889 |
|
clear cell renal carcinoma |
missense_variant |
1.951% (38/1948) |
5 entries |
ENSG00000147889 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
1.97% (16/812) |
3 entries |
ENSG00000147889 |
|
dysplastic nevus |
missense_variant |
9.677% (3/31) |
1 entry |
ENSG00000147889 |
|
pleomorphic xanthoastrocytoma |
transcript_ablation |
13.68% (13/95) |
4 entries |
ENSG00000147889 |
|
osteosarcoma |
transcript_ablation |
7.125% (28/393) |
6 entries |
ENSG00000147889 |
|
diffuse large B-cell lymphoma |
transcript_ablation |
8.402% (81/964) |
9 entries |
ENSG00000147889 |
|
Malignant Urinary System Neoplasm |
sequence_alteration |
18.99% (15/79) |
1 entry |
ENSG00000147889 |
|
bladder transitional cell carcinoma |
amino_acid_insertion |
13.84% (224/1618) |
1 entry |
ENSG00000147889 |
|
breast ductal adenocarcinoma |
missense_variant |
1.388% (29/2090) |
2 entries |
ENSG00000147889 |
|
gastric adenocarcinoma |
missense_variant |
2.334% (33/1414) |
3 entries |
ENSG00000147889 |
|
melanoma |
transcript_ablation |
6.907% (67/970) |
3 entries |
ENSG00000147889 |
|
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
1.97% (16/812) |
2 entries |
ENSG00000147889 |
|
schwannoma |
sequence_alteration |
5.405% (2/37) |
1 entry |
ENSG00000147889 |
|
follicular thyroid carcinoma |
transcript_ablation |
5.785% (7/121) |
1 entry |
ENSG00000147889 |
|
Ovarian Carcinosarcoma |
transcript_ablation |
5.405% (2/37) |
1 entry |
ENSG00000147889 |
|
non-small cell lung carcinoma |
stop_lost |
10.59% (145/1369) |
1 entry |
ENSG00000147889 |
|
soft tissue sarcoma |
missense_variant |
1.458% (5/343) |
2 entries |
ENSG00000147889 |
|
adrenal cortex carcinoma |
sequence_alteration |
2.034% (6/295) |
2 entries |
ENSG00000147889 |
|
lung carcinoma |
stop_gained |
6.79% (11/162) |
1 entry |
ENSG00000147889 |
|
lobular breast carcinoma |
missense_variant |
1.484% (5/337) |
3 entries |
ENSG00000147889 |
|
T-cell acute lymphoblastic leukemia |
amino_acid_insertion |
30.46% (396/1300) |
1 entry |
ENSG00000147889 |
|
Chordoma |
stop_gained |
12.26% (13/106) |
1 entry |
ENSG00000147889 |
|
basal cell carcinoma |
sequence_alteration |
9.135% (19/208) |
1 entry |
ENSG00000147889 |
|
skin carcinoma |
sequence_alteration |
8.197% (10/122) |
1 entry |
ENSG00000147889 |
|
Merkel cell skin cancer |
missense_variant |
4.065% (5/123) |
3 entries |
ENSG00000147889 |
|
Thymic Carcinoma |
stop_gained |
15.0% (9/60) |
3 entries |
ENSG00000147889 |
|
ovarian clear cell adenocarcinoma |
sequence_alteration |
7.692% (11/143) |
4 entries |
ENSG00000147889 |
|
Mantle cell lymphoma |
transcript_ablation |
5.833% (14/240) |
4 entries |
ENSG00000147889 |
|
follicular thyroid carcinoma |
missense_variant |
5.785% (7/121) |
2 entries |
ENSG00000147889 |
|
laryngeal carcinoma |
sequence_alteration |
12.28% (48/391) |
1 entry |
ENSG00000147889 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.554% (19/1223) |
4 entries |
ENSG00000147889 |
|
breast carcinoma |
stop_gained |
1.577% (33/2093) |
2 entries |
ENSG00000147889 |
|
endometrium adenocarcinoma |
frameshift_variant |
4.167% (4/96) |
2 entries |
ENSG00000147889 |
|
hepatocellular carcinoma |
sequence_alteration |
5.767% (97/1682) |
11 entries |
ENSG00000147889 |
|
neoplasm of mature B-cells |
transcript_ablation |
3.235% (11/340) |
3 entries |
ENSG00000147889 |
|
papillary thyroid carcinoma |
sequence_alteration |
3.307% (21/635) |
5 entries |
ENSG00000147889 |
|
Ureter Carcinoma |
sequence_alteration |
37.5% (3/8) |
1 entry |
ENSG00000147889 |
|
angioimmunoblastic T-cell lymphoma |
transcript_ablation |
3.053% (4/131) |
1 entry |
ENSG00000147889 |
|
Barrett's esophagus |
missense_variant |
10.95% (38/347) |
3 entries |
ENSG00000147889 |
|
lung adenocarcinoma |
transcript_ablation |
6.213% (231/3718) |
9 entries |
ENSG00000147889 |
|
squamous cell lung carcinoma |
transcript_ablation |
10.29% (143/1390) |
7 entries |
ENSG00000147889 |
|
embryonal rhabdomyosarcoma |
sequence_alteration |
7.639% (11/144) |
2 entries |
ENSG00000147889 |
|
anaplastic oligoastrocytoma |
sequence_alteration |
11.42% (25/219) |
2 entries |
ENSG00000147889 |
|
follicular thyroid carcinoma |
sequence_alteration |
5.785% (7/121) |
3 entries |
ENSG00000147889 |
|
Non-Functional Pancreatic Neuroendocrine Tumor |
sequence_alteration |
23.81% (5/21) |
2 entries |
ENSG00000147889 |
|
Pleural Mesothelioma |
missense_variant |
37.86% (145/383) |
1 entry |
ENSG00000147889 |
|
Parathyroid Gland Carcinoma |
transcript_ablation |
5.714% (2/35) |
1 entry |
ENSG00000147889 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
5.567% (28/503) |
3 entries |
ENSG00000147889 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
16.67% (12/72) |
1 entry |
ENSG00000147889 |
|
Gallbladder Adenosquamous Carcinoma |
sequence_alteration |
60.0% (3/5) |
1 entry |
ENSG00000147889 |
|
hepatocellular carcinoma |
frameshift_variant |
5.767% (97/1682) |
1 entry |
ENSG00000147889 |
|
chronic lymphocytic leukemia |
missense_variant |
1.43% (19/1329) |
3 entries |
ENSG00000147889 |
|
breast carcinoma |
transcript_ablation |
1.577% (33/2093) |
3 entries |
ENSG00000147889 |
|
angioimmunoblastic T-cell lymphoma |
sequence_alteration |
3.053% (4/131) |
1 entry |
ENSG00000147889 |
|
lung adenocarcinoma |
frameshift_variant |
6.213% (231/3718) |
11 entries |
ENSG00000147889 |
|
ovarian carcinoma |
sequence_alteration |
4.498% (13/289) |
3 entries |
ENSG00000147889 |
|
renal pelvis carcinoma |
sequence_alteration |
50.0% (3/6) |
2 entries |
ENSG00000147889 |
|
esophageal carcinoma |
sequence_alteration |
3.589% (15/418) |
1 entry |
ENSG00000147889 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
7.143% (2/28) |
1 entry |
ENSG00000147889 |
|
melanoma |
missense_variant |
6.907% (67/970) |
8 entries |
ENSG00000147889 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
1.786% (4/224) |
2 entries |
ENSG00000147889 |
|
bile duct carcinoma |
missense_variant |
7.074% (22/311) |
2 entries |
ENSG00000147889 |
|
bronchoalveolar adenocarcinoma |
sequence_alteration |
16.67% (12/72) |
2 entries |
ENSG00000147889 |
|
breast ductal adenocarcinoma |
frameshift_variant |
1.388% (29/2090) |
1 entry |
ENSG00000147889 |
|
cecum adenocarcinoma |
sequence_alteration |
1.444% (4/277) |
2 entries |
ENSG00000147889 |
|
laryngeal carcinoma |
missense_variant |
12.28% (48/391) |
1 entry |
ENSG00000147889 |
|
clear cell renal carcinoma |
stop_gained |
1.951% (38/1948) |
1 entry |
ENSG00000147889 |
|
chronic myelogenous leukemia |
stop_gained |
11.41% (21/184) |
1 entry |
ENSG00000147889 |
|
prostate carcinoma |
sequence_alteration |
1.033% (5/484) |
1 entry |
ENSG00000147889 |
|
extragonadal nonseminomatous germ cell tumor |
sequence_alteration |
16.67% (4/24) |
1 entry |
ENSG00000147889 |
|
actinic keratosis |
sequence_alteration |
3.846% (3/78) |
2 entries |
ENSG00000147889 |
|
malignant peripheral nerve sheath tumor |
transcript_ablation |
18.18% (20/110) |
3 entries |
ENSG00000147889 |
|
oligoastrocytoma |
transcript_ablation |
4.878% (6/123) |
1 entry |
ENSG00000147889 |
|
diffuse large B-cell lymphoma |
missense_variant |
8.402% (81/964) |
4 entries |
ENSG00000147889 |
|
squamous cell lung carcinoma |
missense_variant |
10.29% (143/1390) |
12 entries |
ENSG00000147889 |
|
Ampulla of Vater Carcinoma |
frameshift_variant |
2.03% (4/197) |
1 entry |
ENSG00000147889 |
|
female breast carcinoma |
missense_variant |
2.817% (18/639) |
3 entries |
ENSG00000147889 |
|
colorectal adenocarcinoma |
missense_variant |
2.022% (33/1632) |
4 entries |
ENSG00000147889 |
|
squamous cell lung carcinoma |
conservative_inframe_deletion |
10.29% (143/1390) |
2 entries |
ENSG00000147889 |
|
Borderline Ovarian Brenner Tumor |
transcript_ablation |
50.0% (7/14) |
1 entry |
ENSG00000147889 |
|
cervical squamous cell carcinoma |
missense_variant |
5.274% (26/493) |
3 entries |
ENSG00000147889 |
|
brain glioblastoma |
conservative_inframe_deletion |
17.55% (486/2769) |
1 entry |
ENSG00000147889 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
1.97% (16/812) |
2 entries |
ENSG00000147889 |
|
Benign Ovarian Mucinous Tumor |
transcript_ablation |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
adrenal cortex carcinoma |
missense_variant |
2.034% (6/295) |
3 entries |
ENSG00000147889 |
|
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
9.813% (42/428) |
1 entry |
ENSG00000147889 |
|
basal cell carcinoma |
stop_gained |
9.135% (19/208) |
2 entries |
ENSG00000147889 |
|
melanoma |
frameshift_variant |
6.907% (67/970) |
3 entries |
ENSG00000147889 |
|
lymphoid neoplasm |
sequence_alteration |
6.376% (19/298) |
1 entry |
ENSG00000147889 |
|
nasopharyngeal squamous cell carcinoma |
transcript_ablation |
9.813% (42/428) |
1 entry |
ENSG00000147889 |
|
nasopharyngeal squamous cell carcinoma |
stop_gained |
9.813% (42/428) |
2 entries |
ENSG00000147889 |
|
salivary gland carcinoma |
sequence_alteration |
21.21% (7/33) |
1 entry |
ENSG00000147889 |
|
skin melanoma |
stop_lost |
18.53% (470/2537) |
1 entry |
ENSG00000147889 |
|
papillary thyroid carcinoma |
stop_gained |
3.307% (21/635) |
1 entry |
ENSG00000147889 |
|
salivary gland carcinoma |
transcript_ablation |
21.21% (7/33) |
1 entry |
ENSG00000147889 |
|
chronic lymphocytic leukemia |
transcript_ablation |
1.43% (19/1329) |
2 entries |
ENSG00000147889 |
|
alveolar rhabdomyosarcoma |
sequence_alteration |
4.444% (4/90) |
2 entries |
ENSG00000147889 |
|
breast carcinoma |
missense_variant |
1.577% (33/2093) |
6 entries |
ENSG00000147889 |
|
Anaplastic (Malignant) Meningioma |
transcript_ablation |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
Gallbladder Adenocarcinoma |
frameshift_variant |
14.61% (45/308) |
1 entry |
ENSG00000147889 |
|
pharyngeal squamous cell carcinoma |
sequence_alteration |
8.284% (28/338) |
5 entries |
ENSG00000147889 |
|
Invasive Breast Carcinoma |
missense_variant |
5.797% (4/69) |
1 entry |
ENSG00000147889 |
|
mesenchymal chondrosarcoma |
transcript_ablation |
6.667% (3/45) |
1 entry |
ENSG00000147889 |
|
hepatocellular carcinoma |
stop_gained |
5.767% (97/1682) |
5 entries |
ENSG00000147889 |
|
seborrheic keratosis |
sequence_alteration |
11.54% (3/26) |
1 entry |
ENSG00000147889 |
|
large cell lung carcinoma |
sequence_alteration |
10.81% (12/111) |
5 entries |
ENSG00000147889 |
|
sebaceous adenocarcinoma |
missense_variant |
80.0% (4/5) |
1 entry |
ENSG00000147889 |
|
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
sequence_alteration |
6.542% (7/107) |
2 entries |
ENSG00000147889 |
|
pharyngeal squamous cell carcinoma |
frameshift_variant |
8.284% (28/338) |
6 entries |
ENSG00000147889 |
|
adrenal cortex carcinoma |
transcript_ablation |
2.034% (6/295) |
1 entry |
ENSG00000147889 |
|
colorectal adenocarcinoma |
sequence_alteration |
2.022% (33/1632) |
5 entries |
ENSG00000147889 |
|
alveolar rhabdomyosarcoma |
missense_variant |
4.444% (4/90) |
2 entries |
ENSG00000147889 |
|
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
9.231% (6/65) |
1 entry |
ENSG00000147889 |
|
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
transcript_ablation |
6.542% (7/107) |
1 entry |
ENSG00000147889 |
|
chronic pancreatitis |
sequence_alteration |
22.22% (10/45) |
1 entry |
ENSG00000147889 |
|
Thymoma Type B3 |
transcript_ablation |
3.39% (2/59) |
1 entry |
ENSG00000147889 |
|
squamous cell carcinoma |
stop_gained |
33.33% (9/27) |
1 entry |
ENSG00000147889 |
|
bladder carcinoma |
stop_gained |
6.078% (62/1020) |
2 entries |
ENSG00000147889 |
|
diffuse gastric adenocarcinoma |
transcript_ablation |
5.97% (12/201) |
2 entries |
ENSG00000147889 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
5.567% (28/503) |
5 entries |
ENSG00000147889 |
|
central nervous system primitive neuroectodermal neoplasm |
transcript_ablation |
1.099% (6/546) |
2 entries |
ENSG00000147889 |
|
Vulvar Squamous Cell Carcinoma |
sequence_alteration |
18.8% (25/133) |
1 entry |
ENSG00000147889 |
|
breast carcinoma |
sequence_alteration |
1.577% (33/2093) |
5 entries |
ENSG00000147889 |
|
carcinoma of liver and intrahepatic biliary tract |
frameshift_variant |
4.613% (34/737) |
1 entry |
ENSG00000147889 |
|
pulmonary mucoepidermoid carcinoma |
transcript_ablation |
50.0% (3/6) |
2 entries |
ENSG00000147889 |
|
meningioma (disease) |
sequence_alteration |
4.79% (8/167) |
1 entry |
ENSG00000147889 |
|
Ovarian Yolk Sac Tumor |
sequence_alteration |
50.0% (2/4) |
2 entries |
ENSG00000147889 |
|
acute lymphoblastic leukemia |
missense_variant |
9.167% (55/600) |
2 entries |
ENSG00000147889 |
|
melanoma |
sequence_alteration |
6.907% (67/970) |
7 entries |
ENSG00000147889 |
|
breast phyllodes tumor |
transcript_ablation |
7.071% (7/99) |
3 entries |
ENSG00000147889 |
|
neoplasm of mature B-cells |
missense_variant |
3.235% (11/340) |
2 entries |
ENSG00000147889 |
|
lung adenocarcinoma |
stop_lost |
6.213% (231/3718) |
1 entry |
ENSG00000147889 |
|
ovarian carcinoma |
missense_variant |
4.498% (13/289) |
2 entries |
ENSG00000147889 |
|
bile duct adenocarcinoma |
sequence_alteration |
3.761% (29/771) |
5 entries |
ENSG00000147889 |
|
colon adenocarcinoma |
sequence_alteration |
2.561% (37/1445) |
8 entries |
ENSG00000147889 |
|
papillary thyroid carcinoma |
missense_variant |
3.307% (21/635) |
3 entries |
ENSG00000147889 |
|
metaplastic breast carcinoma |
missense_variant |
9.412% (8/85) |
3 entries |
ENSG00000147889 |
|
brain astrocytoma |
sequence_alteration |
7.463% (5/67) |
1 entry |
ENSG00000147889 |
|
basal cell carcinoma |
missense_variant |
9.135% (19/208) |
3 entries |
ENSG00000147889 |
|
melanoma |
stop_gained |
6.907% (67/970) |
7 entries |
ENSG00000147889 |
|
squamous cell lung carcinoma |
frameshift_variant |
10.29% (143/1390) |
9 entries |
ENSG00000147889 |
|
Thymic Carcinoma |
sequence_alteration |
15.0% (9/60) |
2 entries |
ENSG00000147889 |
|
urothelial carcinoma |
missense_variant |
6.522% (6/92) |
1 entry |
ENSG00000147889 |
|
myelodysplastic syndrome |
sequence_alteration |
0.5171% (5/967) |
1 entry |
ENSG00000147889 |
|
squamous cell lung carcinoma |
sequence_alteration |
10.29% (143/1390) |
16 entries |
ENSG00000147889 |
|
chronic myelogenous leukemia |
sequence_alteration |
11.41% (21/184) |
3 entries |
ENSG00000147889 |
|
hepatocellular carcinoma |
transcript_ablation |
5.767% (97/1682) |
1 entry |
ENSG00000147889 |
|
endometrium adenocarcinoma |
missense_variant |
4.167% (4/96) |
1 entry |
ENSG00000147889 |
|
Intestinal Type Adenocarcinoma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
Hodgkins lymphoma |
sequence_alteration |
6.667% (1/15) |
1 entry |
ENSG00000147889 |
|
Duodenal Adenocarcinoma |
frameshift_variant |
5.882% (1/17) |
1 entry |
ENSG00000147889 |
|
cervical adenocarcinoma |
stop_gained |
4.348% (1/23) |
1 entry |
ENSG00000147889 |
|
Thymic Squamous Cell Carcinoma |
frameshift_variant |
14.29% (2/14) |
1 entry |
ENSG00000147889 |
|
unspecified peripheral T-cell lymphoma |
stop_gained |
4.237% (5/118) |
1 entry |
ENSG00000147889 |
|
oligoastrocytoma |
stop_gained |
4.878% (6/123) |
1 entry |
ENSG00000147889 |
|
Unclassified Renal Cell Carcinoma |
stop_gained |
4.082% (2/49) |
1 entry |
ENSG00000147889 |
|
Salivary Gland Large Cell Carcinoma |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000147889 |
|
Salivary Gland Small Cell Carcinoma |
sequence_alteration |
33.33% (1/3) |
1 entry |
ENSG00000147889 |
|
dedifferentiated chondrosarcoma |
transcript_ablation |
8.571% (3/35) |
1 entry |
ENSG00000147889 |
|
Tracheal Squamous Cell Carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000147889 |
|
ovarian serous adenocarcinoma |
frameshift_variant |
1.554% (19/1223) |
1 entry |
ENSG00000147889 |
|
Mixed Lobular and Ductal Breast Carcinoma |
frameshift_variant |
9.231% (6/65) |
1 entry |
ENSG00000147889 |
|
Biphasic Mesothelioma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
Duodenal Gastrin-Producing Neuroendocrine Tumor |
sequence_alteration |
4.762% (1/21) |
1 entry |
ENSG00000147889 |
|
Endometrial Clear Cell Adenocarcinoma |
stop_gained |
7.143% (2/28) |
1 entry |
ENSG00000147889 |
|
Parotid Gland Squamous Cell Carcinoma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000147889 |
|
multiple myeloma |
sequence_alteration |
0.813% (2/246) |
1 entry |
ENSG00000147889 |
|
cervical squamous cell carcinoma |
stop_gained |
5.274% (26/493) |
1 entry |
ENSG00000147889 |
|
endodermal sinus tumor |
frameshift_variant |
20.0% (2/10) |
1 entry |
ENSG00000147889 |
|
Endometrial Endometrioid Adenocarcinoma |
transcript_ablation |
1.97% (16/812) |
1 entry |
ENSG00000147889 |
|
Ampulla of Vater Carcinoma |
missense_variant |
2.03% (4/197) |
1 entry |
ENSG00000147889 |
|
clear cell sarcoma |
sequence_alteration |
10.0% (3/30) |
1 entry |
ENSG00000147889 |
|
Submandibular Gland Adenoid Cystic Carcinoma |
frameshift_variant |
16.67% (1/6) |
1 entry |
ENSG00000147889 |
|
Chordoma |
sequence_alteration |
12.26% (13/106) |
1 entry |
ENSG00000147889 |
|
Gastric Small Cell Neuroendocrine Carcinoma |
sequence_alteration |
33.33% (1/3) |
1 entry |
ENSG00000147889 |
|
Invasive Breast Carcinoma |
transcript_ablation |
5.797% (4/69) |
1 entry |
ENSG00000147889 |
|
renal cell carcinoma |
missense_variant |
2.899% (2/69) |
1 entry |
ENSG00000147889 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
12.58% (41/326) |
1 entry |
ENSG00000147889 |
|
mouth mucous membrane leukoplakia |
sequence_alteration |
50.0% (2/4) |
1 entry |
ENSG00000147889 |
|
medullary thyroid gland carcinoma |
missense_variant |
1.77% (2/113) |
1 entry |
ENSG00000147889 |
|
actinic keratosis |
stop_gained |
3.846% (3/78) |
1 entry |
ENSG00000147889 |
|
large cell lung carcinoma |
conservative_inframe_deletion |
10.81% (12/111) |
1 entry |
ENSG00000147889 |
|
Meningothelial Meningioma |
sequence_alteration |
14.29% (1/7) |
1 entry |
ENSG00000147889 |
|
Pleural Epithelioid Mesothelioma |
frameshift_variant |
12.58% (41/326) |
1 entry |
ENSG00000147889 |
|
ependymoma |
sequence_alteration |
1.418% (2/141) |
1 entry |
ENSG00000147889 |
|
Thymic Squamous Cell Carcinoma |
amino_acid_insertion |
14.29% (2/14) |
1 entry |
ENSG00000147889 |
|
Parotid Gland Acinic Cell Carcinoma |
transcript_ablation |
8.333% (1/12) |
1 entry |
ENSG00000147889 |
|
Primary Effusion Lymphoma |
sequence_alteration |
4.348% (1/23) |
1 entry |
ENSG00000147889 |
|
kidney Wilms tumor |
missense_variant |
0.295% (1/339) |
1 entry |
ENSG00000147889 |
|
acute lymphoblastic leukemia |
stop_gained |
9.167% (55/600) |
1 entry |
ENSG00000147889 |
|
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000147889 |
|
Colorectal Neuroendocrine Tumor G1 |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000147889 |
|
Signet Ring Cell Gastric Adenocarcinoma |
transcript_ablation |
16.67% (1/6) |
1 entry |
ENSG00000147889 |
|
myelodysplastic syndrome |
frameshift_variant |
0.5171% (5/967) |
1 entry |
ENSG00000147889 |
|
head and neck carcinoma |
stop_gained |
83.33% (5/6) |
1 entry |
ENSG00000147889 |
|
pancreatic neoplasm |
sequence_alteration |
2.381% (2/84) |
1 entry |
ENSG00000147889 |
|
mucosal melanoma |
stop_gained |
2.597% (2/77) |
1 entry |
ENSG00000147889 |
|
prostate adenocarcinoma |
amino_acid_insertion |
1.213% (30/2473) |
1 entry |
ENSG00000147889 |
|
Ocular Sebaceous Carcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
papilloma |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000147889 |
|
ovarian teratoma |
stop_gained |
16.92% (11/65) |
1 entry |
ENSG00000147889 |
|
unspecified peripheral T-cell lymphoma |
transcript_ablation |
4.237% (5/118) |
1 entry |
ENSG00000147889 |
|
salivary gland adenoid cystic carcinoma |
frameshift_variant |
4.412% (3/68) |
1 entry |
ENSG00000147889 |
|
Basaloid Carcinoma |
transcript_ablation |
22.22% (2/9) |
1 entry |
ENSG00000147889 |
|
dedifferentiated chondrosarcoma |
stop_gained |
8.571% (3/35) |
1 entry |
ENSG00000147889 |
|
renal carcinoma |
transcript_ablation |
3.704% (1/27) |
1 entry |
ENSG00000147889 |
|
Pleural Epithelioid Mesothelioma |
stop_gained |
12.58% (41/326) |
1 entry |
ENSG00000147889 |
|
chronic myelomonocytic leukemia |
missense_variant |
0.4219% (1/237) |
1 entry |
ENSG00000147889 |
|
ovarian adenocarcinoma |
sequence_alteration |
4.762% (1/21) |
1 entry |
ENSG00000147889 |
|
Tracheal Squamous Cell Carcinoma |
stop_gained |
33.33% (1/3) |
1 entry |
ENSG00000147889 |
|
endodermal sinus tumor |
sequence_alteration |
20.0% (2/10) |
1 entry |
ENSG00000147889 |
|
adenosquamous lung carcinoma |
frameshift_variant |
6.25% (2/32) |
1 entry |
ENSG00000147889 |
|
seborrheic keratosis |
frameshift_variant |
11.54% (3/26) |
1 entry |
ENSG00000147889 |
|
Duodenal Adenocarcinoma |
stop_gained |
5.882% (1/17) |
1 entry |
ENSG00000147889 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
1.97% (16/812) |
1 entry |
ENSG00000147889 |
|
Ovarian Granulosa Cell Tumor |
sequence_alteration |
3.03% (1/33) |
1 entry |
ENSG00000147889 |
|
Ureter Carcinoma |
missense_variant |
37.5% (3/8) |
1 entry |
ENSG00000147889 |
|
Basaloid Carcinoma |
sequence_alteration |
22.22% (2/9) |
1 entry |
ENSG00000147889 |
|
Skin Basosquamous Cell Carcinoma |
transcript_ablation |
100.0% (2/2) |
1 entry |
ENSG00000147889 |
|
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
missense_variant |
6.542% (7/107) |
1 entry |
ENSG00000147889 |
|
malignant rhabdoid tumour |
transcript_ablation |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
diffuse gastric adenocarcinoma |
frameshift_variant |
5.97% (12/201) |
1 entry |
ENSG00000147889 |
|
Anaplastic (Malignant) Meningioma |
stop_gained |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
neoplasm of mature B-cells |
frameshift_variant |
3.235% (11/340) |
1 entry |
ENSG00000147889 |
|
colorectal adenocarcinoma |
stop_gained |
2.022% (33/1632) |
1 entry |
ENSG00000147889 |
|
gastric adenocarcinoma |
conservative_inframe_deletion |
2.334% (33/1414) |
1 entry |
ENSG00000147889 |
|
mucosal melanoma |
transcript_ablation |
2.597% (2/77) |
1 entry |
ENSG00000147889 |
|
undifferentiated pleomorphic sarcoma |
frameshift_variant |
4.425% (5/113) |
1 entry |
ENSG00000147889 |
|
pulmonary mucoepidermoid carcinoma |
sequence_alteration |
50.0% (3/6) |
1 entry |
ENSG00000147889 |
|
B-cell neoplasm |
missense_variant |
2.083% (2/96) |
1 entry |
ENSG00000147889 |
|
Barrett's esophagus |
conservative_inframe_deletion |
10.95% (38/347) |
1 entry |
ENSG00000147889 |
|
Peritoneal Mesothelioma |
transcript_ablation |
6.667% (2/30) |
1 entry |
ENSG00000147889 |
|
small cell lung carcinoma |
stop_gained |
2.45% (16/653) |
1 entry |
ENSG00000147889 |
|
colon carcinoma |
frameshift_variant |
12.5% (1/8) |
1 entry |
ENSG00000147889 |
|
vulvar intraepithelial neoplasia |
stop_gained |
7.692% (1/13) |
1 entry |
ENSG00000147889 |
|
small intestinal adenocarcinoma |
sequence_alteration |
3.846% (1/26) |
1 entry |
ENSG00000147889 |
|
Salivary Gland Large Cell Carcinoma |
stop_gained |
20.0% (1/5) |
1 entry |
ENSG00000147889 |
|
Submandibular Gland Adenoid Cystic Carcinoma |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000147889 |
|
epidermal appendage tumor |
stop_gained |
42.86% (3/7) |
1 entry |
ENSG00000147889 |
|
ependymoma |
transcript_ablation |
1.418% (2/141) |
1 entry |
ENSG00000147889 |
|
alveolar rhabdomyosarcoma |
stop_gained |
4.444% (4/90) |
1 entry |
ENSG00000147889 |
|
mesenchymal chondrosarcoma |
sequence_alteration |
6.667% (3/45) |
1 entry |
ENSG00000147889 |
|
colon adenoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000147889 |
|
unspecified peripheral T-cell lymphoma |
missense_variant |
4.237% (5/118) |
1 entry |
ENSG00000147889 |
|
B-cell neoplasm |
sequence_alteration |
2.083% (2/96) |
1 entry |
ENSG00000147889 |
|
clear cell sarcoma |
transcript_ablation |
10.0% (3/30) |
1 entry |
ENSG00000147889 |
|
Mixed Lobular and Ductal Breast Carcinoma |
sequence_alteration |
9.231% (6/65) |
1 entry |
ENSG00000147889 |
|
Burkitts lymphoma |
missense_variant |
4.938% (12/243) |
1 entry |
ENSG00000147889 |
|
liposarcoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000147889 |
|
Rhabdoid Meningioma |
transcript_ablation |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
Sarcomatoid Mesothelioma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
amelanotic skin melanoma |
transcript_ablation |
50.0% (1/2) |
1 entry |
ENSG00000147889 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
3.526% (11/312) |
1 entry |
ENSG00000147889 |
|
Pancreatic Acinar Cell Carcinoma |
sequence_alteration |
2.703% (1/37) |
1 entry |
ENSG00000147889 |
|
hairy cell leukemia |
sequence_alteration |
3.03% (1/33) |
1 entry |
ENSG00000147889 |
|
small cell lung carcinoma |
stop_lost |
2.45% (16/653) |
1 entry |
ENSG00000147889 |
|
Parotid Gland Squamous Cell Carcinoma |
stop_gained |
7.692% (1/13) |
1 entry |
ENSG00000147889 |
|
chondrosarcoma |
sequence_alteration |
4.0% (1/25) |
1 entry |
ENSG00000147889 |
|
medullary thyroid gland carcinoma |
sequence_alteration |
1.77% (2/113) |
1 entry |
ENSG00000147889 |
|
HER2 Positive Breast Carcinoma |
stop_gained |
1.786% (4/224) |
1 entry |
ENSG00000147889 |
|
Mantle cell lymphoma |
missense_variant |
5.833% (14/240) |
1 entry |
ENSG00000147889 |
|
Eccrine Porocarcinoma |
stop_gained |
20.0% (1/5) |
1 entry |
ENSG00000147889 |
|
nasal cavity and paranasal sinus carcinoma |
missense_variant |
4.651% (2/43) |
1 entry |
ENSG00000147889 |
|
cecum adenocarcinoma |
missense_variant |
1.444% (4/277) |
1 entry |
ENSG00000147889 |
|
anaplastic large cell lymphoma |
sequence_alteration |
3.448% (1/29) |
1 entry |
ENSG00000147889 |
|
Benign Ovarian Mucinous Tumor |
conservative_inframe_deletion |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
oligoastrocytoma |
missense_variant |
4.878% (6/123) |
1 entry |
ENSG00000147889 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
1.213% (30/2473) |
1 entry |
ENSG00000147889 |
|
bile duct adenocarcinoma |
frameshift_variant |
3.761% (29/771) |
1 entry |
ENSG00000147889 |
|
large cell neuroendocrine carcinoma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
lung carcinoid tumor |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000147889 |
|
colon adenoma |
sequence_alteration |
5.556% (1/18) |
1 entry |
ENSG00000147889 |
|
urothelial carcinoma |
sequence_alteration |
6.522% (6/92) |
1 entry |
ENSG00000147889 |
|
nasal cavity and paranasal sinus carcinoma |
stop_gained |
4.651% (2/43) |
1 entry |
ENSG00000147889 |
|
salivary gland mucoepidermoid carcinoma |
transcript_ablation |
16.67% (1/6) |
1 entry |
ENSG00000147889 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
1.099% (6/546) |
1 entry |
ENSG00000147889 |
|
ovarian clear cell adenocarcinoma |
missense_variant |
7.692% (11/143) |
1 entry |
ENSG00000147889 |
|
Ovarian Dysgerminoma |
sequence_alteration |
50.0% (1/2) |
1 entry |
ENSG00000147889 |
|
Malignant Ovarian Mixed Epithelial Tumor |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000147889 |
|
angiosarcoma |
transcript_ablation |
2.985% (2/67) |
1 entry |
ENSG00000147889 |
|
salivary gland carcinoma |
frameshift_variant |
21.21% (7/33) |
1 entry |
ENSG00000147889 |
|
Sarcomatoid Mesothelioma |
stop_gained |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
leiomyosarcoma |
missense_variant |
2.525% (5/198) |
1 entry |
ENSG00000147889 |
|
B-cell neoplasm |
stop_gained |
2.083% (2/96) |
1 entry |
ENSG00000147889 |
|
Chordoma |
missense_variant |
12.26% (13/106) |
1 entry |
ENSG00000147889 |
|
adenosquamous lung carcinoma |
missense_variant |
6.25% (2/32) |
1 entry |
ENSG00000147889 |
|
vulvar intraepithelial neoplasia |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000147889 |
|
diffuse large B-cell lymphoma |
frameshift_variant |
8.402% (81/964) |
1 entry |
ENSG00000147889 |
|
endometrium adenocarcinoma |
sequence_alteration |
4.167% (4/96) |
1 entry |
ENSG00000147889 |
|
spindle cell sarcoma |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
lung adenocarcinoma |
amino_acid_insertion |
6.213% (231/3718) |
1 entry |
ENSG00000147889 |
|
Sinonasal Undifferentiated Carcinoma |
sequence_alteration |
8.333% (1/12) |
1 entry |
ENSG00000147889 |
|
salivary gland adenoid cystic carcinoma |
missense_variant |
4.412% (3/68) |
1 entry |
ENSG00000147889 |
|
Benign Ovarian Mucinous Tumor |
frameshift_variant |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
seborrheic keratosis |
missense_variant |
11.54% (3/26) |
1 entry |
ENSG00000147889 |
|
Pleural Biphasic Mesothelioma |
missense_variant |
14.63% (18/123) |
1 entry |
ENSG00000147889 |
|
endometrium adenocarcinoma |
stop_gained |
4.167% (4/96) |
1 entry |
ENSG00000147889 |
|
Unclassified Renal Cell Carcinoma |
missense_variant |
4.082% (2/49) |
1 entry |
ENSG00000147889 |
|
sebaceous adenocarcinoma |
sequence_alteration |
80.0% (4/5) |
1 entry |
ENSG00000147889 |
|
dysplastic nevus |
sequence_alteration |
9.677% (3/31) |
1 entry |
ENSG00000147889 |
|
Eccrine Porocarcinoma |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000147889 |
|
Peritoneal Mesothelioma |
frameshift_variant |
6.667% (2/30) |
1 entry |
ENSG00000147889 |
|
metaplastic breast carcinoma |
sequence_alteration |
9.412% (8/85) |
1 entry |
ENSG00000147889 |
|
Basaloid Carcinoma |
frameshift_variant |
22.22% (2/9) |
1 entry |
ENSG00000147889 |
|
Atypical Meningioma |
transcript_ablation |
2.222% (1/45) |
1 entry |
ENSG00000147889 |
|
cervical adenocarcinoma |
sequence_alteration |
4.348% (1/23) |
1 entry |
ENSG00000147889 |
|
follicular thyroid carcinoma |
frameshift_variant |
5.785% (7/121) |
1 entry |
ENSG00000147889 |
|
prostate carcinoma |
missense_variant |
1.033% (5/484) |
1 entry |
ENSG00000147889 |
|
ovarian carcinoma |
frameshift_variant |
4.498% (13/289) |
1 entry |
ENSG00000147889 |
|
endometrium adenocarcinoma |
transcript_ablation |
4.167% (4/96) |
1 entry |
ENSG00000147889 |
|
actinic keratosis |
missense_variant |
3.846% (3/78) |
1 entry |
ENSG00000147889 |
|
malignant peripheral nerve sheath tumor |
sequence_alteration |
18.18% (20/110) |
1 entry |
ENSG00000147889 |
|
multiple myeloma |
stop_gained |
0.813% (2/246) |
1 entry |
ENSG00000147889 |
|
keratoacanthoma |
stop_gained |
1.471% (1/68) |
1 entry |
ENSG00000147889 |
|
angiosarcoma |
sequence_alteration |
2.985% (2/67) |
1 entry |
ENSG00000147889 |
|
brain astrocytoma |
missense_variant |
7.463% (5/67) |
1 entry |
ENSG00000147889 |
|
Ocular Sebaceous Carcinoma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000147889 |
|
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
0.8772% (1/114) |
1 entry |
ENSG00000147889 |
|
mucosal melanoma |
missense_variant |
2.597% (2/77) |
1 entry |
ENSG00000147889 |
|
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
transcript_ablation |
9.091% (5/55) |
1 entry |
ENSG00000147889 |
|
head and neck carcinoma |
missense_variant |
83.33% (5/6) |
1 entry |
ENSG00000147889 |
|
renal cell carcinoma |
transcript_ablation |
2.899% (2/69) |
1 entry |
ENSG00000147889 |
|
Uveal Melanoma |
transcript_ablation |
0.7463% (2/268) |
1 entry |
ENSG00000147889 |
|
liposarcoma |
stop_gained |
1.429% (1/70) |
1 entry |
ENSG00000147889 |
|
large cell lung carcinoma |
frameshift_variant |
10.81% (12/111) |
1 entry |
ENSG00000147889 |
|
small cell lung carcinoma |
conservative_inframe_deletion |
2.45% (16/653) |
1 entry |
ENSG00000147889 |
|
colon carcinoma |
sequence_alteration |
12.5% (1/8) |
1 entry |
ENSG00000147889 |
|
metaplastic breast carcinoma |
stop_gained |
9.412% (8/85) |
1 entry |
ENSG00000147889 |
|
malignant peripheral nerve sheath tumor |
frameshift_variant |
18.18% (20/110) |
1 entry |
ENSG00000147889 |
|
carcinosarcoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000147889 |
|
Skin Basosquamous Cell Carcinoma |
stop_gained |
100.0% (2/2) |
1 entry |
ENSG00000147889 |
|
Colorectal Neuroendocrine Tumor G1 |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000147889 |
|
Uveal Melanoma |
frameshift_variant |
0.7463% (2/268) |
1 entry |
ENSG00000147889 |
|
lobular breast carcinoma |
stop_gained |
1.484% (5/337) |
1 entry |
ENSG00000147889 |
|
Undifferentiated Ovarian Carcinoma |
missense_variant |
11.76% (2/17) |
1 entry |
ENSG00000147889 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
0.8772% (1/114) |
1 entry |
ENSG00000147889 |
|
breast ductal adenocarcinoma |
stop_gained |
1.388% (29/2090) |
1 entry |
ENSG00000147889 |
|
Benign Ovarian Mucinous Tumor |
sequence_alteration |
32.0% (8/25) |
1 entry |
ENSG00000147889 |
|
Intestinal Type Adenocarcinoma |
conservative_inframe_deletion |
100.0% (1/1) |
1 entry |